A roundtable discussion with Drs Axel Grothey and Michael J
Overman on recent developments in the treatment of colorectal
cancer, including the following topics:
Biomarker analysis for patients with colorectal cancer (CRC)
(00:00)
Effect of tumor sidedness on prognosis and response to therapy
(4:28)
Sequencing of systemic therapy for patients with metastatic CRC
(mCRC); selection of patients for therapy with EGFR antibodies
(8:51)
Role of BRAF mutations and the recently FDA-approved
combination of encorafenib and cetuximab for patients with mCRC
with a BRAF V600E mutation (17:56)
Response to BRAF-targeted therapies in patients with BRAF V600E
mutations (28:45)
Ongoing investigation of mechanisms of resistance to
BRAF-targeted therapies (36:20)
Efficacy of immune checkpoint inhibitors pembrolizumab,
nivolumab and nivolumab/ipilimumab in patients with mCRC; effect of
MSI status on response to immunotherapy (38:11)
Effect of POLE mutations and tumor mutation burden (TMB) on
response to checkpoint inhibitors; recent approval of pembrolizumab
for patients with unresectable or metastatic TMB-high
(≥10 mut/Mb) solid tumors (47:36)
Potential role of immune checkpoint inhibitors in patients with
mCRC who have microsatellite-stable disease (58:32)
Integration of TAS-102 and regorafenib in the management of
mCRC (1:06:26)
Dosing considerations and tolerability of regorafenib;
association of tumor cavitation and response to regorafenib
(1:13:12)
Sequencing of TAS-102 and regorafenib in mCRC (1:16:51)
Response to the combination of regorafenib and nivolumab among
patients with mCRC (1:22:51)
Targeting HER2 in mCRC; activity and side-effect profile of
trastuzumab deruxtecan (1:29:39)
Novel agents and strategies under investigation for patients
with mCRC (1:38:23)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.